Dr Sophie Harding joins AWTTC to lead pharmacogenomics delivery in Wales

10 April 2026

Dr Sophie Harding, Consultant Pharmacist for Genomics and Pharmacogenomics joined the All Wales Therapeutics and Toxicology Centre (AWTTC) on 1 April.

Dr Harding has significant expertise in pharmacogenomics (PGx) and has already played a central role in shaping its future in Wales. She led the development of the PGx Delivery Plan for Wales 2026–2029, which sets out a national strategy to embed pharmacogenomic testing into routine clinical practice across NHS Wales. The programme aims to improve treatment effectiveness, reduce adverse drug reactions, and enhance patient outcomes.

The Delivery Plan has recently received formal approval following endorsement by the National Pharmacogenomics Group and Genomics Partnership Wales Governance board. Final sign-off was granted by the NHS Planned Care Programme Board on 24 March. A supporting document outlining the resource requirements needed to implement the plan in Wales was also approved.

Work is now progressing to establish the governance framework and programme structure required to deliver the plan. A National PGx Oversight Committee will be established to provide strategic leadership and expert guidance. The committee will also be responsible for governance, monitoring, and assurance, including formal reporting on programme progress to Genomics Partnership Wales and the Welsh Government.

Dr Harding’s appointment at AWTTC represents a significant step forward for pharmacogenomics in Wales, strengthening AWTTC’s role in supporting the delivery of this ambitious national programme to improve patient care.